The Carbomedics prosthetic heart valve: four year follow-up in 100 patients.
From December 1988 to December 1991, 100 patients underwent valve replacement with a Carbomedics bileaflet valve in our institution (55 aortic valve replacements, 28 mitral valve replacements, and 17 double valve replacements). Fifty-nine percent were males. Mean age was 55.7+/-12.3 years. Fifty eight percent of patients were in NYHA Clinical status III or IV. Operative mortality was 3% (3/100). All patients but one were followed up for an average of 2.8 years after their operation and total follow-up was 280 patient years. At the time of the study, more than 80% of patients were in NYHA class I or II, 34% were in atrial fibrillation and 100% of patients received anticoagulation treatment. There were 3 late deaths. After 4 years, the actuarial survival rate was 94%+/-5%. No patients died of valve-related causes. Valve-related complications included 2 thromboembolic episodes (0.7%-patient-year), 8 anticoagulant-related complications (2% patient-year), and one reoperation (0.3% patient-year). After 4 years, freedom from thromboembolic complication was 96%+/-4%, from endocarditis was 100%, from reoperation was 99%+/-1%, and from anticoagulant-related complications was 93%+/-5%. We conclude that the 4-year results compare with other bileaflet valves. More follow-up and larger studies are mandated to give definite conclusions.
Aupart
M R
MR
Department of Cardiac Surgery, Trousseau University Hospital, Tours, France.
El Hammami
S
S
Diemont
F
F
Sirinelli
A L
AL
Bah
A
A
Marchand
M A
MA
D000328:Adult; D000368:Aged; D001021:Aortic Valve / Q000601:surgery; D005260:Female; D005500:Follow-Up Studies; D006350:Heart Valve Prosthesis / Q000401:mortality*; D006801:Humans; D008297:Male; D008875:Middle Aged; D008943:Mitral Valve / Q000601:surgery; D011183:Postoperative Complications; D012086:Reoperation; D015996:Survival Rate; D013923:Thromboembolism / Q000209:etiology